Suspended psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Suspended is a registry status. The study stopped early but may start again. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 6 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 2 |
| Ketamine | 4 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 2 | 33% |
| Phase 2 | 1 | 17% |
| Phase 3 | 1 | 17% |
| Phase 4 | 1 | 17% |
| Not applicable | 1 | 17% |
Countries
Country is taken from the study's linked research site. 0 of 6 records have no country on file. The top 2 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 4 | 67% |
| Canada | 2 | 33% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 2 |
| 2020 to 2023 | 3 |
| 2015 to 2019 | 1 |
Study design
- 6 interventional and 0 observational studies.
- Median planned or actual enrolment is 25 participants (range 5 to 240, across 6 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 2 |
| Trauma and PTSD | 1 |
| Other substance use | 1 |
| Suicidal thoughts | 1 |
Most recently started studies
The 6 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT06378528 | Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) | Suspended | Early Phase 1 | United States | 2026-03 |
| NCT06102434 | Safety Profile of Psilocybin for Cocaine Use Disorder | Suspended | Early Phase 1 | United States | 2026-02 |
| NCT05832255 | An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome | Suspended | Phase 2 | Canada | 2023-03 |
| NCT05719909 | Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment | Suspended | Not applicable | United States | 2023-02 |
| NCT04640636 | IM Ketamine vs Midazolam for Suicidal ER Patients | Suspended | Phase 4 | United States | 2021-02 |
| NCT03674671 | Ketamine Versus Electroconvulsive Therapy in Depression | Suspended | Phase 3 | Canada | 2018-10 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable